 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for February 13, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| LMT... | Hot Stocks20:15 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Lockheed Martin (LMT) announced it has terminated its agreement to acquire Aerojet Rocketdyne (AJRD). The decision to terminate the agreement follows the U.S. Federal Trade Commission's lawsuit filed late last month seeking a preliminary injunction to block the acquisition. 2. Amazon (AMZN) and Spotify (SPOT) are considering rival takeover approaches for Audioboom, the London-listed podcasting group which has seen revenues and its share price surge during the pandemic, Sky News' Mark Kleinman reported. Sky News has learnt that the two digital behemoths have been exploring bids for Audioboom in recent weeks, and could decide whether to make formal offers as soon as this month. 3. Since the start of 2020, chip stocks are up 82%, easily beating the 54% gain for the Nasdaq Composite. Big names like AMD (AMD) and Nvidia (NVDA) have gotten much of the attention, but a little-known chip maker has beat them all: Synaptics (SYNA), Eric J. Savitz wrote in this week's edition of Barron's. Once a low-key provider of chips used for PC touchpads, mobile phone screens, and fingerprint scanners, Synaptics has turned itself into a play on the Internet of Things, which aims to bridge the physical and digital worlds, the author noted. In recent months, though, Synaptics has been caught up in the broader tech selloff, with shares down 28% from their December peak. The pullback is a good entry point for investors who missed the original rally, Savitz contended. 4. Disney's (DIS) "Death on the Nile" won the Super Bowl weekend - usually a challenge for Hollywood studios - with a $12.8M debut as the ongoing pandemic continues to keep older moviegoers away from theaters. Overseas, the Agatha Christie adaptation opened to $20.7M for a global cume of $34M. 5. Boyd Gaming (BYD), Bally's (BALY), Caesars (CZR), Caterpillar (CAT), CNH Industrial (CNHI), Procter & Gamble (PG), Philip Morris (PM), Ford (F), and Disney saw positive mentions in this week's edition of Barron's.
|
| AJRD LMT | Hot Stocks19:06 EST Aerojet reaffirms 'strong foundation for substantial value creation' - Aerojet Rocketdyne (AJRD) announced termination of merger agreement with Lockheed Martin (LMT) and reaffirmed its "strong foundation for substantial value creation." The company said in a statement, "We are poised to deliver substantial value to our shareholders driven by our continued leadership in key space exploration and defense growth markets, including by advancing hypersonics and strategic, tactical and missile defense systems. Aerojet Rocketdyne has delivered strong shareholder returns of 166% over the five years prior to the transaction announcement, significantly outperforming the Aerospace and Defense Index by 33% and the S&P 500 by 62%. We are confident in our future performance with an impressive backlog that is more than three times the size of our annual sales and a strong macroeconomic environment underpinning our portfolio. We look forward to providing further details regarding our financial performance and strategy on our fourth quarter and full year 2021 earnings report on Feb. 17, 2022."
|
| LMT AJRD | Hot Stocks19:05 EST Lockheed Martin terminates agreement to acquire Aerojet Rocketdyne - Lockheed Martin (LMT) announced it has terminated its agreement to acquire Aerojet Rocketdyne (AJRD). The decision to terminate the agreement follows the U.S. Federal Trade Commission's lawsuit filed late last month seeking a preliminary injunction to block the acquisition. "Our planned acquisition of Aerojet Rocketdyne would have benefited the entire industry through greater efficiency, speed, and significant cost reductions for the U.S. government," said Lockheed Martin Chairman, President and CEO James Taiclet. "However, we determined that in light of the FTC's actions, terminating the transaction is in the best interest of our stakeholders. We stand by our long heritage as a merchant supplier and trusted partner and will continue to support Aerojet Rocketdyne and other essential suppliers in the Defense Industrial Base still overcoming the challenges of the pandemic. Moving forward, we will maintain our focus on the most effective use of capital with the highest return on investment, including our ongoing commitment to return value to shareholders. We remain confident in our company's strong foundation and growth potential as several exciting projects enter production."
|
| EYPT | Hot Stocks16:03 EST EyePoint announces updated interim data from ongoing Phase 1 DAVIO trial - EyePoint Pharmaceuticals announced updated interim data from the Durasert and Vorolanib in Ophthalmology, or DAVIO, Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor treatment targeting wet age-related macular degeneration. The interim eight-month follow-up data presented from the Phase 1 DAVIO clinical trial continue to show no reports of ocular serious adverse events or drug-related systemic SAEs. There have been no reported events of vitreous floaters, endophthalmitis, retinal detachment, implant migration in the anterior chamber, retinal vasculitis, or posterior segment inflammation. These data also show that 41% of eyes did not require any supplemental anti-VEGF injections up to nine months following a single dose of EYP-1901. Additionally, updated data from the eight-month follow-up confirm stable best corrected visual acuity, stable central subfield thickness on optical coherence tomography, and a clinically significant 75% reduction in treatment burden. The Phase 1 DAVIO trial is an open-label, dose escalation clinical trial of EYP-1901 that enrolled 17 patients with previously treated wet AMD. EYP-1901 is a sustained delivery anti-VEGF investigational treatment that utilizes a bioerodible formulation of EyePoint's Durasert drug delivery technology that has been utilized in four FDA-approved products, including EyePoint's YUTIQ for chronic non-infectious uveitis affecting the posterior segment of the eye. EyePoint plans to initiate a Phase 2 trial of EYP-1901 in wet AMD in the third quarter of this year, informed by a positive Type C meeting with U.S. Food and Drug Administration in December 2021. The trial is expected to enroll 144 patients, randomly assigned to one of two doses of EYP-1901 or aflibercept control, with the primary efficacy endpoint of change in BCVA and secondary endpoints of change in CST, as measured by OCT, time to supplemental anti-VEGF injection and safety.
|
